(Q38417521)

2 September 2017

1 reference

title

Emerging drugs for the treatment of knee osteoarthritis (English)

1 reference

2 September 2017

1 reference

Shirley Pei-Chun Yu

1

1 reference

2 September 2017

David John Hunter

series ordinal

2

1 reference

2 September 2017

language of work or name

English

0 references

publication date

12 April 2015

1 reference

Expert Opinion on Emerging Drugs

2 September 2017

published in

1 reference

2 September 2017

volume

20

1 reference

2 September 2017

issue

3

1 reference

2 September 2017

page(s)

361-378

1 reference

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Lower extremity osteoarthritis management needs a paradigm shift

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Projections of US prevalence of arthritis and associated activity limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Role of inflammation in the pathogenesis of osteoarthritis: latest findings and interpretations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Inflammation in osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

The role of synovitis in osteoarthritis pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Osteoarthritis: a disease of the joint as an organ

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Clinical significance of bone changes in osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

21 January 2018

Aging and osteoarthritis

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Aging processes and the development of osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Synovitis detected on magnetic resonance imaging and its relation to pain and cartilage loss in knee osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

OARSI guidelines for the non-surgical management of knee osteoarthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Lifetime medical costs of knee osteoarthritis management in the United States: impact of extending indications for total knee arthroplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Therapy switching, augmentation, and discontinuation in patients with osteoarthritis and chronic low back pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Patient satisfaction after total knee arthroplasty: who is satisfied and who is not?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

What proportion of patients report long-term pain after total hip or knee replacement for osteoarthritis? A systematic review of prospective studies in unselected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Management of chronic knee pain: a survey of patient preferences and treatment received

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Staggered overdose pattern and delay to hospital presentation are associated with adverse outcomes following paracetamol-induced hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Paracetamol in osteoarthritis of the knee

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Comparing rates of dyspepsia with Coxibs vs NSAID+PPI: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

The comparative safety of analgesics in older adults with arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

The future of osteoarthritis therapeutics: targeted pharmacological therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

The burden of hip osteoarthritis in the United States: epidemiologic and economic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Disease-modifying drugs for knee osteoarthritis: can they be cost-effective?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Health economics in the field of osteoarthritis: an expert's consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Direct and indirect costs of pain therapy for osteoarthritis in an insured population in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Pharmacologic therapy for osteoarthritis--the era of disease modification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Tanezumab for the treatment of pain from osteoarthritis of the knee.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Introduction to purinergic signalling in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Purinergic receptors and pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Analgesic profile of intrathecal P2X(3) antisense oligonucleotide treatment in chronic inflammatory and neuropathic pain states in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Arthritis and pain. Future targets to control osteoarthritis pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Current and emerging "at-site" pain medications: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Antinociceptive properties of a non-nucleotide P2X3/P2X2/3 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Circulating levels of IL-6 and TNF-α are associated with knee radiographic osteoarthritis and knee cartilage loss in older adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Treatment of erosive osteoarthritis of the hands by intra-articular infliximab injections: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Anti-inflammatory and cartilage-protecting effects of an intra-articularly injected anti-TNF{alpha} single-chain Fv antibody (ESBA105) designed for local therapeutic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Mitogen-activated protein kinases as therapeutic targets in osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

IGF-I stimulation of proteoglycan synthesis by chondrocytes requires activation of the PI 3-kinase pathway but not ERK MAPK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Novel strategies for inhibition of the p38 MAPK pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

New pharmacologic approaches in the management of osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Emerging drugs for osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

VAP-1: an adhesin and an enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

In vivo detection of vascular adhesion protein-1 in experimental inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

VAP-1 and CD73, endothelial cell surface enzymes in leukocyte extravasation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Bradykinin potentiates cytokine-induced prostaglandin biosynthesis in osteoblasts by enhanced expression of cyclooxygenase 2, resulting in increased RANKL expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Bradykinin and B₂ receptor antagonism in rat and human articular chondrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Novel effects mediated by bradykinin and pharmacological characterization of bradykinin B2 receptor antagonism in human synovial fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Antagonism of bradykinin B2 receptor prevents inflammatory responses in human endothelial cells by quenching the NF-kB pathway activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Contrast-enhanced ultrasound in monitoring the efficacy of a bradykinin receptor 2 antagonist in painful knee osteoarthritis compared with MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Knee osteoarthritis: a role for bradykinin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Three-dimensional structure of recombinant human osteogenic protein 1: structural paradigm for the transforming growth factor beta superfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Effect of interleukin-1beta on osteogenic protein 1-induced signaling in adult human articular chondrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Alterations in endogenous osteogenic protein-1 with degeneration of human articular cartilage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Fibroblast growth factor-18 stimulates chondrogenesis and cartilage repair in a rat model of injury-induced osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Biological impact of the fibroblast growth factor family on articular cartilage and intervertebral disc homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Exuberant expression of chemokine genes by adult human articular chondrocytes in response to IL-1beta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Functional articular cartilage repair: here, near, or is the best approach not yet clear?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

MEPE is a novel regulator of growth plate cartilage mineralization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

ASARM-truncated MEPE and AC-100 enhance osteogenesis by promoting osteoprogenitor adhesion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

A synthetic peptide fragment of human MEPE stimulates new bone formation in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Platelet-rich plasma for managing pain and inflammation in osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Tendon healing and platelet-rich plasma therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

TLR4 signalling in osteoarthritis--finding targets for candidate DMOADs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

The catabolic pathway mediated by Toll-like receptors in human osteoarthritic chondrocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

NF-kappaB signaling: multiple angles to target OA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Molecular basis of anti-inflammatory action of platelet-rich plasma on human chondrocytes: mechanisms of NF-κB inhibition via HGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Efficacy of platelet-rich plasma injections in osteoarthritis of the knee: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Platelet-rich plasma vs hyaluronic acid to treat knee degenerative pathology: study design and preliminary results of a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

A randomized clinical trial evaluating plasma rich in growth factors (PRGF-Endoret) versus hyaluronic acid in the short-term treatment of symptomatic knee osteoarthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Comparison of intra-articular injections of plasma rich in growth factors (PRGF-Endoret) versus Durolane hyaluronic acid in the treatment of patients with symptomatic osteoarthritis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Platelet-rich plasma intra-articular injection versus hyaluronic acid viscosupplementation as treatments for cartilage pathology: from early degeneration to osteoarthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Treatment with platelet-rich plasma is more effective than placebo for knee osteoarthritis: a prospective, double-blind, randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Deletion of the transforming growth factor β receptor type II gene in articular chondrocytes leads to a progressive osteoarthritis-like phenotype in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Mesenchymal stem cells in joint disease and repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Mesenchymal stem cells for cartilage repair in osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Age-dependent alteration of TGF-β signalling in osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Regeneration of the articular surface of the rabbit synovial joint by cell homing: a proof of concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Stem cell therapy in a caprine model of osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Calcitonin affects both bone and cartilage: a dual action treatment for osteoarthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Effects of calcitonin on knee osteoarthritis and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthri

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Bisphosphonates for osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Bisphosphonates for osteoarthritis prevention: "Holy Grail" or not?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Guidelines for the medical management of osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

Platelet-rich plasma intra-articular injections for cartilage degeneration and osteoarthritis: single- versus double-spinning approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2015.1037275

10.1517/14728214.2015.1037275

21 January 2018

Identifiers

DOI

1 reference

2 September 2017

1 reference